Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 5Phase 1 5Phase 1/2 4Phase NA 1Phase 4 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 72Gastrointestinal 17CNS 8Thoracic 6Tumor-Agnostic 4Gynecologic 3Other solid neoplasm 2Head & Neck 2Genitourinary 2Sarcoma 1Plasma cell 1Myeloid 1Dermatologic 1

Conditions

Neoplasm Metastasis 3Neoplasms 2Carcinoma 1

Interventions

pembrolizumab 18Nivolumab 18Gemcitabine 9Ipilimumab 8Cisplatin 8Carboplatin 8Capecitabine 8Paclitaxel 6Cetuximab 6atezolizumab 5Irinotecan 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5avelumab 4Trastuzumab 4Fluorouracil 4trametinib 3spartalizumab 3Specimen Handling 3Pemetrexed 3Leucovorin 3Everolimus 3Dexamethasone 3Biopsy 3urelumab 2toripalimab 2tislelizumab 2ribociclib 2repotrectinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Trastuzumab × Tumor-Agnostic × Clear all
NCT04802759 2026-05-11

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Hoffmann-La Roche

Phase 1/2 Recruiting
316 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01271920 2020-12-08

Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

Novartis

Phase 1/2 Completed
45 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00954512 2018-08-24

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
15 enrolled 11 charts
Tumor-Agnostic

Neoplasms

NCT00031278 2011-05-30

Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer

Pfizer

Phase 1/2 Completed
12 enrolled
Tumor-Agnostic

Carcinoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡